Adarasib adagrasib 200mg

Product Information

• Catalog product: TLPH Adarasib adagrasib 200mg
• Listed manufacturer: TLPH Pharma, Laos
• Active ingredient and strength: adagrasib, 200mg
• AISTIKA SKU: AM-ITEM-1

Product Summary

Adarasib is the TLPH adagrasib 200mg listing in the AISTIKA catalog. Match this name, strength and SKU to the requested item rather than selecting a medicine by its packaging photograph alone. The price and availability shown above belong to this listing; they are not a comparison with another manufacturer’s pack.

Active Ingredient and Reference Data

The medical reference below concerns the active ingredient, not a regulatory assessment of this TLPH product. It does not establish that Adarasib is approved in your country or interchangeable with another brand. The linked US label was updated on August 31, 2026. Older pages and search snippets may describe indications that are no longer current.

Mechanism of Action

Adagrasib inhibits the KRAS G12C protein involved in cancer-cell signaling. A KRAS mutation is not automatically the G12C variant: molecular testing matters when an oncology team considers this treatment. A target-directory match is a way to find catalog entries, not a treatment recommendation. See the NCI ingredient overview for background; use the current label and FDA withdrawal record for indication status.

Reference Indications

The current US label covers single-agent treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after at least one systemic therapy, with mutation confirmation using an FDA-approved test. This remains an accelerated-approval indication.

Important update: FDA lists the adagrasib-plus-cetuximab colorectal-cancer indication as withdrawn on September 1, 2026. It must not be described here as a currently FDA-approved use. The withdrawal is indication-specific, not a statement that every adagrasib use was withdrawn.

Reference Dosage and Administration

The US reference dosage is 600mg twice daily, with or without food; tablets are swallowed whole. For a 200mg strength, 600mg equals three tablets per dose only when that regimen is prescribed. Toxicity can require dose changes. A physician must determine treatment and a pharmacist must check the supplied package insert.

Important Safety Information

Serious gastrointestinal effects, QT prolongation, liver injury and interstitial lung disease/pneumonitis require clinical assessment. New breathing difficulty, fainting or severe persistent vomiting warrants urgent medical attention.

Common Adverse Reactions and Monitoring

Nausea, diarrhea, vomiting and fatigue are common. Clinicians monitor liver tests and, according to risk, ECGs and electrolytes. This summary is not the complete adverse-reaction list.

Drug Interactions and Special Populations

CYP3A-related interactions and QT-prolonging medicines need pharmacist review. Discuss pregnancy and breastfeeding before treatment; do not breastfeed during therapy.

Storage and Purchase Notes

Follow the actual pack’s storage instructions, not conditions copied from another brand. Before ordering, confirm the pack quantity, expiry, batch details and any destination-specific requirements. This page does not promise customs clearance, availability in every jurisdiction or a particular shipping condition.

Medical information basis: official public product labeling and regulatory safety information.

Disclaimer

Educational catalog information only, not an individualized prescription or proof of local authorization, authenticity or therapeutic equivalence. Consult a qualified physician or pharmacist about suitability and the supplied product’s labeling. Do not start, switch or adjust cancer treatment from a catalog description.